COMP <GO>
TMDX vs MRK // FREE CASH FLOW YIELD
TransMedics Group Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: TMDX 6
— MRK 7
▲ FREE CASH FLOW YIELD LEADER: TMDX
LAST: $65.99 (-1.68%) • MKT CAP: $2.33B
fcf-yield
5.74%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 74.80% | -14.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 20.70% | -2.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.6x | 15.3x | -0.70 | TMDX | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 5.74% | 3.42% | +2.32 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | 34.30% | -16.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 28.10% | +3.30 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 1.30% | +35.80 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 5.19 | -1.69 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 51.7 | -19.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | 18.4x | -8.20 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $361.02B | -$358.69B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | MRK REV | TMDX GROSS % | MRK GROSS % | TMDX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $65.01B | 59.9% | 74.8% | $133.6M | $12.36B |
| FY 2024 | $441.5M | $64.17B | 59.4% | 76.3% | -$80.9M | $18.10B |
| FY 2023 | $241.6M | $60.12B | — | — | -$13.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
MRK // BETA 0.92